Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD

BACKGROUND: CHF6001 is a novel inhaled phosphodiesterase-4 inhibitor. This Phase IIa study assessed the effects of CHF6001 on markers of inflammation in induced sputum and blood in patients with chronic obstructive pulmonary disease (COPD). METHODS: This was a multicentre, three-period (each 32 days...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Dave, Beeh, Kai Michael, Colgan, Brendan, Kornmann, Oliver, Leaker, Brian, Watz, Henrik, Lucci, Germano, Geraci, Silvia, Emirova, Aida, Govoni, Mirco, Nandeuil, Marie Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688371/
https://www.ncbi.nlm.nih.gov/pubmed/31399091
http://dx.doi.org/10.1186/s12931-019-1142-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688371/
https://www.ncbi.nlm.nih.gov/pubmed/31399091
http://dx.doi.org/10.1186/s12931-019-1142-7

Ejemplares similares